Results 21 to 30 of about 200,878 (264)

Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?

Current Oncology, 2023
Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing ...
Ezra Hahn, Danielle Rodin, Rinku Sutradhar, Sharon Nofech-Mozes, Sabina Trebinjac, Lawrence Frank Paszat, Eileen Rakovitch   +6 more
doaj   +1 more source

Breast Ductal Carcinoma In Situ [PDF]

International Journal of Surgical Oncology, 2012
Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there
V. Sacchini, L. Fortunato, H. S. Cody Iii, K. J. Van Zee, B. Cutuli, B. Bonanni   +5 more
openaire   +2 more sources

Manejo quirúrgico del cáncer de piel. Servicio de dermatología, Hospital de San José, Bogotá DC, Colombia

Repertorio de Medicina y Cirugía, 2013
Introducción: el cáncer de piel representa un problema de salud pública que se puede prevenir y manejar con éxito ante el diagnóstico temprano. Objetivo: describir las características clínicas, histopatológicas, poblacionales y quirúrgicas del cáncer de ...
Oscar Mora H., Manuel Fernando Ortíz, Angélica Guatibonza H., Itala Merlano Caropresse   +3 more
doaj   +1 more source

Nasopharyngeal carcinoma in situ in nasopharyngeal carcinoma. [PDF]

Journal of Clinical Pathology, 1992
AIMS: To assess the presence of carcinoma in situ (CIS) in patients with nasopharyngeal carcinoma (NPC) and to see if the number of biopsy sites facilitates detection of CIS. METHODS: Formalin fixed, paraffin wax embedded biopsy specimens (n = 285) from 187 patients with NPC in 1987 were studied for the presence of CIS as well as for the histological ...
Chan, CW, Choy, D, Sham, JST, Dickens, P, Nicholls, JM   +4 more
openaire   +3 more sources

A rare case of extensive ductal carcinoma in situ of the breast with secretory features

Rare Tumors, 2012
We report a very rare case of extensive ductal carcinoma in situ (DCIS) of the breast with secretory features in a 30-year old Japanese woman. The patient presented with a nodule in the lower inner quadrant of the left breast measuring approximately 2-3 ...
Kenichi Sugihara, Tsuyoshi Nakagawa, Shigeo Kawai, Takeo Iwama, Akira Iwasaki, Takanobu Sato   +5 more
doaj   +1 more source

Association of clinico-pathological and immunohistochemical prognostic parameters with presence of ductal carcinoma in-situ in an invasive ductal carcinoma of breast

Journal of Pathology of Nepal, 2023
Background: The clinical outcome of breast carcinoma varies in each individual due to its molecular heterogeneity. There is a rising interest in whether the associated ductal carcinoma in-situ in invasive ductal carcinoma of breast affects the prognosis ...
Dhivya Balaiya, Anitha Chellam Annadurai, Jayakarthiga Subbiah Rajasekaran   +2 more
doaj   +1 more source

Nasal septal pediculate carcinoma in situ: differential diagnosis

São Paulo Medical Journal
Pediculated lesions of the nasal cavities are relatively common in daily practice, and include inflammatory polyps, benign tumors (papillomas being the most common), malignant tumors, and specific processes, such as polypoid rhinosporidiosis. The authors
Edmir Américo Lourenço, Luís Henrique Chechinato Costa   +1 more
doaj   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

RIPK4 function interferes with melanoma cell adhesion and metastasis

Molecular Oncology, EarlyView.
RIPK4 promotes melanoma growth and spread. RIPK4 levels increase as skin lesions progress to melanoma. CRISPR/Cas9‐mediated deletion of RIPK4 causes melanoma cells to form less compact spheroids, reduces their migratory and invasive abilities and limits tumour growth and dissemination in mouse models.
Norbert Wronski, Sławomir Lasota, Ewelina Madej, Anna A. Brożyna, Małgorzata Szczygieł, Agnieszka Harazin‐Lechowska, Jan Czerbniak, Janusz Rys, Jaroslaw Czyz, Agnieszka Wolnicka‐Glubisz   +9 more
wiley   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

Molecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang   +12 more
wiley   +1 more source